Phoenix-based Cutaneous NeuroDiagnostics (d/b/a CND Life Sciences), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). Todd Levine, MD, a neuromuscular neurologist and CND’s co-founder and chief medical officer, will serve as the principal investigator (PI) on the two-year grant.

“We are honored to receive this prestigious NIH grant,” says Levine. “The award will support the largest study of its kind to enhance the precision and clinical utility of our Syn-One Test, which is being adopted by neurologists to improve the diagnosis of neurodegenerative disorders, notably Parkinson’s disease.”

The NIH grant allows CND to conduct a 500-patient, multicenter clinical study with leading neurologists and academic centers across the United States. The study aims to further validate the sensitivity and specificity of CND’s Syn-One Test to distinguish between the different types of synucleinopathies. This large-scale scientific assessment of CND’s diagnostic approach and pathological methods will provide physicians and patients with even greater evidence to support broad clinical adoption of the Syn-One Test.  

“CND is determined to improve how physicians diagnose and treat patients with signs and symptoms of neurodegenerative diseases, especially early in the disease process,” says Richard Morello, chief executive officer, CND Life Sciences. “Advancing a convenient, minimally invasive test that can offer physicians and patients a higher degree of confidence and accuracy in the diagnosis of difficult diseases like Parkinson’s and dementia with Lewy bodies will help the field take a big step forward.”

For more information visit CND Life Sciences.

Featured image: The Syn-One Test is being adopted by neurologists to improve the diagnosis of neurodegenerative disorders. (Courtesy: CND Life Sciences)